Lung Cancer

Can earlier navigation help patients with stage III NSCLC reach treatment faster? See how one community cancer center paired early navigator involvement with targeted workflow changes to reduce delays in care.

Durvalumab consolidation therapy improved overall and progression-free survival in patients with limited-stage small cell lung cancer that did not progress after standard-of-care concurrent chemoradiotherapy.

Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.

A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.

Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.

A recently released study found a significant concordance rate drop between liquid and tissue biopsies via next-generation sequencing when patients had disease progression.

A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation.

A Canadian study found that next-generation sequencing identified more mutations, had a faster turnaround time, and was more cost-effective than single-gene testing when used in patients with non–small cell lung cancer.

A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.

A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.